Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes, and animals.
Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.
Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.
Celcuity is a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies.
Be Biopharma pioneers engineered B cell medicines aimed at improving treatments for conditions like Hemophilia B and cancer. Their innovative approach utilizes precision genome editing to create durable and effective cell therapies.
Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerate innovation in biological research and engineering.
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated the best-in-class platform and initiated multiple programs across different disease areas.
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers. Founded by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman in 2020 and is headquartered in Durham, North Carolina.
Ocelot Bio brings new treatment options to patients with severe liver disease. It researches and discovers medicines that help in the treatment of hepatorenal syndrome, a complication of severe liver disease.
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of true drug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas.
Somatus is a healthcare company that partners with health plans, health systems, nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia and is founded by a team of healthcare operators, entrepreneurs, and clinicians who treat kidney disease.
Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. The company was founded in 2012 and is based in Redwood City, California.
Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells, and depletes pathological immune cells. ELA026 is in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory condition for which there is no approved treatment.
Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers.
Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Ventus' structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system.
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases.
AN2 Therapeutics, Inc. is a California-based global health biopharmaceutical company focused on modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. The company was founded in 2017 and is headquartered in Menlo Park, California, United States.
AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.
Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
Nodexus is a Venture- and SBIR-backed biotech startup commercializing the NX One platform to address widespread unmet needs for accessible live single cell isolation in industrial/biopharma, clinical research, and academic sectors. The NX One platform consists of a low-infrastructure, low-cost hardware system and single-use disposable microfluidic cartridges tailored toward live single-cell workflows involving gene editing (e.g. CRISPR engineering), cell line/antibody development, and tumor heterogeneity studies.
Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.
NanoMosaic provides solutions for early illness detection, prognostic monitoring, and biomarker identification. Its protein interrogation powered by nanoneedles enables early disease detection, prognostic monitoring, and biomarker discovery on a single chip. .
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads.
Avilar Therapeutics is a biopharmaceutical company focusing on the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation.
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
Cedilla is a developer of therapeutics technologies intended to broaden the reach of small molecule therapeutics. The company's technology is focused on destabilizing oncoprotein targets that are also applicable to therapies outside of oncology, enabling doctors to treat diseases caused by protein dysregulation. The company was founded in 2018 and based in Cambridge, Massachusetts.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts.
Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California.
ARS Pharmaceuticals is a stealth pharmaceutical company that developed a novel intranasal epinephrine spray with a unique absorption technology that could be easy-to-use, convenient, and more reliable for patients and loved ones at risk of severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis.
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Jnana Therapeutics is a biotechnology company focused on discovering and developing medicines that improve patient lives. Utilizing its RAPID platform, the firm accelerates the identification of therapeutic targets and the creation of small molecule therapies for various diseases. Jnana aims to enhance drug discovery efficiency through advanced chemoproteomics techniques, addressing unmet medical needs.
Tango Therapeutics operator of a biotechnology company created to discover novel drug targets and deliver the next generation of targeted therapies to people with cancer. The company's research leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer that are focused on three core areas, including counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations, enabling patients to get therapies that are more effective than single-agent therapy.
GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases. The early-stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system. GentiBio is a Seattle, Washington-headquartered company launched in 2020 by Adel Nada, Chandra Patel, and Andy Walker.
Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible.
Thriveworks offer a variety of mental health services, including depression therapy, marriage counseling, life coaching, & more.
Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines. Its platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins that make them accessible to small-molecule drug discovery and development.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.
Element Biosciences is a life science company that focuses on developing innovative genetic analysis tools. The company is developing a modular and high-performing DNA sequencing platform that will deliver high-quality data, workflow flexibility, and make next-generation sequencing technology more accessible. The company's proprietary approach to improving the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation, and biochemistry to drastically decrease the run and capital costs while delivering high sequencing data quality.
Adela develops innovative and accessible technologies focusing on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. Adela’s genome-wide methylome enrichment platform captures information efficiently from the entire methylome. Its technology distinguishes the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially targets those regions for sequencing.
LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes. Its program is an aceclidine-based eye drop designed to restore the loss of near vision associated with presbyopia.
Synthekine is an engineered cytokine therapeutics company that creates selective immunotherapies to improve cancer and inflammatory disease treatment paradigms. Using knowledge of cytokine structure and function, the company develops therapeutics that maximize cytokine efficacy while avoiding toxic side effects. Synthekine is developing a broad and deep pipeline of product candidates by leveraging principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms. Modified cytokines, cytokine-enhanced cell therapies, and surrogate cytokine agonists are among the novel immunotherapies.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline. Eliem Therapeutics develops and commercializes potentially “best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.
Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.
Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective. The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision-making. The Ceribell EEG System can be set up by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.
Forge Biologics is a gene therapy development engine, focused on enabling access to life-changing gene therapies and helping bring them from an idea into reality. The company partners with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. It was founded in 2020 and headquartered in Grove City, Ohio.
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response.
Invivyd is a commercial-stage biopharmaceutical company that delivers protection from serious viral infectious diseases. It is on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2.
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Ventus' structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system.
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.
New Equilibrium Biosciences provides a platform that reveals opportunities for structure-based design by learning biophysics with AI.
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra’s lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline. Eliem Therapeutics develops and commercializes potentially “best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations.
Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response.
Century Therapeutics builds an allogeneic iPSC-derived cell therapy platform that integrates gene editing, protein engineering, technical development, and manufacturing capabilities to generate allogeneic, iPSC-derived NK and T cell therapies for both hematological and solid tumor malignancies with significant unmet medical needs.
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.
Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.
Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery. Making accessible the broad set of proteins expressed in human cells, the company’s platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients.
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of people of all ages living with cancer starting from the biology of childhood cancer. Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies.
Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases.
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
Abcuro’s mission is to develop immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by their founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system.
Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway. At Vivace Therapeutics, they pursue their work with passion, driven by a conviction to help people fight cancer and live life to the fullest. Based in the San Francisco Bay Area, Vivace Therapeutics is an oncology-focused portfolio-based drug discovery and development company adopting a capital-efficient and modality-indifferent approach to bring novel therapies to patients in need. Their experienced management team and world-class scientists work to advance promising drugs and therapeutic technologies that they believe can help conquer cancer.
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has an estimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.
Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.
Adagio Medical is engaged in the research and development of treatments for cardiovascular diseases. Adagio Medical is committed to providing electrophysiologists innovative cryoablation catheters that create safe, continuous, transmural lesions to treat cardiac arrhythmias anywhere in the heart, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. The company was founded in 2011 and is based in Laguna Hills, California.
Cytek Biosciences is a manufacturer and supplier of flow cytometry products and services.
Be Biopharma pioneers engineered B cell medicines aimed at improving treatments for conditions like Hemophilia B and cancer. Their innovative approach utilizes precision genome editing to create durable and effective cell therapies.